All ETDs from UAB

Advisory Committee Chair

Suzanne Lapi

Advisory Committee Members

Norman Bolus

Remo George

Document Type


Date of Award


Degree Name by School

Master of Science (MS) School of Health Professions


Imaging with radiolabelled peptides is an important technique used in medical imaging fields that can lead to significant advances in patient care. These tracers are utilized to target a variety of receptors, in particular, specific-receptors which are overexpressed on tumor cells. Recently, the application of Positron Emission Tomography (PET) radiotracers for medical imaging has grown significantly due to the high sensitivity and specificity of this technique. In particular, 68Ga is one of the most favorable PET radioisotopes, due to its short half-life, low radiation dose, generator production, and same day imaging procedures. [68Ga]-DOTATATE, which targets somatostatin receptors (SSTR) overexpressed on neuroendocrine tumors (NETs), is the first 68Ga imaging agent approved by the FDA. [68Ga]-PSMA compounds have also been widely explored for imaging of prostate cancer. Recent reports of imaging with other newly developed [68Ga]-labeled peptides in both clinical and preclinical trials have shown the feasibility of imaging other tumor-specific receptors and biomarkers of other diseases. This review will discuss the recent progress of [68Ga]-labeled radiopharmaceuticals in imaging of various diseases in both clinical and preclinical trials outside of SSTR and PSMA imaging.